<code id='FC24C04B6B'></code><style id='FC24C04B6B'></style>
    • <acronym id='FC24C04B6B'></acronym>
      <center id='FC24C04B6B'><center id='FC24C04B6B'><tfoot id='FC24C04B6B'></tfoot></center><abbr id='FC24C04B6B'><dir id='FC24C04B6B'><tfoot id='FC24C04B6B'></tfoot><noframes id='FC24C04B6B'>

    • <optgroup id='FC24C04B6B'><strike id='FC24C04B6B'><sup id='FC24C04B6B'></sup></strike><code id='FC24C04B6B'></code></optgroup>
        1. <b id='FC24C04B6B'><label id='FC24C04B6B'><select id='FC24C04B6B'><dt id='FC24C04B6B'><span id='FC24C04B6B'></span></dt></select></label></b><u id='FC24C04B6B'></u>
          <i id='FC24C04B6B'><strike id='FC24C04B6B'><tt id='FC24C04B6B'><pre id='FC24C04B6B'></pre></tt></strike></i>

          Home / comprehensive / comprehensive

          comprehensive


          comprehensive

          author:focus    Page View:1

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In